





Laboratory diagnosis for Covid-19 in Children




Gholamreza Pouladfar MD
Subspecialty in Pediatric Infectious Diseases
Shiraz University of Medical Sciences
Oct. 2012



Importance of Lab tests

- **Epidemiological purpose**
 - the main tools for the promotion, prevention, and control of infectious diseases
 - two main categories: immunological and molecular.
- **Clinical purposes**

Who should (and should not) be tested for SARS-CoV-2 infection?



- **Patients with symptoms consistent with COVID-19**
- **Patients in close contact**
 - a distance of less than 6 feet for at least 15 minutes from a person with laboratory-confirmed
 - **Wearing a mask or cloth covering**
 - **They** is presently not considered sufficient to alleviate the risk of transmission if close contact conditions are met. **Confirmed or probable SARS-CoV-2 infection**
- **Patients scheduled for an invasive medical procedure**
 - An elective surgery

Suggested priorities for SARS-CoV-2 (COVID-19) testing

Priority	IDSA guidance ^[1]
First/High priority	<ul style="list-style-type: none"><li data-bbox="754 354 2257 501">■ Critically ill patients receiving ICU-level care with unexplained viral pneumonia or respiratory failure (regardless of travel or exposure history)<li data-bbox="754 518 2257 768">■ Any individual (including health care workers) with fever or features of a lower respiratory tract illness and close contact with patients with laboratory-confirmed COVID-19 within 14 days of symptom onset (including all residents of long-term care facilities with a confirmed case)<li data-bbox="754 785 2321 932">■ Individuals with fever or features of a lower respiratory tract illness who are also immunosuppressed (including patients with HIV), older, or have underlying chronic health conditions<li data-bbox="754 949 2295 1146">■ Individuals with fever or features of a lower respiratory tract illness who are critical to the pandemic response, including health care workers, public health officials, and other essential leaders
Second/Priority	<ul style="list-style-type: none"><li data-bbox="754 1203 2321 1350">■ Non-ICU hospitalized patients and long-term care residents with unexplained fever and features of a lower respiratory tract illness^{*,†}

Suggested priorities for SARS-CoV-2 (COVID-19) testing

Third	<ul style="list-style-type: none">■ Outpatients who meet criteria for influenza testing (eg, symptoms such as fever, cough, and other suggestive respiratory symptoms plus comorbid conditions, such as diabetes mellitus, chronic obstructive pulmonary disease, congestive heart failure, age >50 years, immunocompromising conditions); testing of outpatient pregnant women and symptomatic children with similar risk factors is also included in this priority level*
Fourth	<ul style="list-style-type: none">■ Community surveillance as directed by public health and/or infectious diseases authorities

What is the outpatient testing criteria?

- varies according to test availability and other resources
- for **symptomatic patients** (eg, fever, persistent cough) who are otherwise stable but have either:
 - **Underlying conditions** (eg, immune compromise, chronic cardiac or pulmonary disease)
 - Known **in-person exposure** to a laboratory-confirmed case of COVID-19 within the previous 14 days

An underlying condition that may increase the **risk for severe disease**; examples include

- 1) An immune-compromising condition
 - (eg, recipients of antineoplastic chemotherapy, recent hematopoietic cell transplantation, solid organ transplant recipients, primary immunodeficiency, HIV infection with CD4 count <15 percent)
- 2) Chronic cardiac disease
 - (eg, cardiomyopathy, unrepaired cyanotic congenital heart disease, single ventricle physiology)
- 3) Chronic pulmonary disease
 - (eg, requirement for supplemental oxygenation or noninvasive ventilation, severe persistent asthma)
- 4) Former preterm infants
- 5) Neuromuscular disease with impaired airway clearance
- 6) Poorly controlled type I diabetes mellitus
- 7) Severe obesity
 - (body mass index ≥ 120 percent of the 95th percentile values)

When should **patients** be tested after starting **symptoms consistent with COVID-19** ?

- a) without delay
- b) 2-4 days
- c) 5-7 days
- d) After one week

a

When should asymptomatic patients with **close contact** exposure to infected persons be tested?

- a) without delay
- b) 2-3 days after exposure
- c) At least 4 days after exposure
- d) At least 7 days after exposure



The probability of a false-negative result in an infected person decreases substantially over the first 4 days after exposure.

Because symptoms develop 2 to 14 days following exposure and most commonly between 5 and 6 days

C

What means a **single negative test** in a close contact?

- A single negative test does not mean you **will remain negative** at any time point after that test.
- Even if there is a negative test, a person with a close contact should still **self-isolate for 14 days**.

Testing is not generally recommended for
.....? (more than 1 response)

- a) Exposure to a **close contact who is asymptomatic**
- b) Exposure to a close contact who is symptomatic
- c) Exposure to a close contact who subsequently tests positive
- d) Symptomatic **close contact who have previously tested positive** within the past 3 months.
- e) Symptomatic patients with COVID-19 for **return to school/work** clearance



a, d, e

Which one is the “gold standard” for testing an individual child for acute SARS-CoV-2 infection?

A. PCR tests


B. Antigen tests

C. Antibody tests



A

PCR test



Which one is the **most often respiratory samples** that PCR tests perform on it?


- A. Throat swab
- B. nasopharyngeal swab
- C. Nasal swab
- D. Sputum



B

RT-PCR performance by time since symptom onset or exposure

- The estimated rates of **false-negative**
 - a) **100 %** on the day of exposure
 - b) **38 %** on day 5 (estimated as the first day of symptoms)
 - c) **20 %** at day 8
 - d) **66 %** at day 21



Days

-5

0

5

10

15

20

25

Windows of false negatives

RT-PCR

Serological tests

Activate Windows

Antigens tests

- 1) Tests that detect SARS-CoV-2 antigen
 - 2) **more accessible** with **a faster time** to results than some molecular studies
- WHO advise:
 - a) A minimum **sensitivity ≥ 80** percent and specificity ≥ 97 percent,
 - b) within **the first five to seven days** of symptoms

Which is not correct about antigen tests ?

- a) They generally performed on **nasal or oral swab** specimens
- b) They are the **point-of-care** test.
- c) They generally have **lower sensitivity** than molecular tests.
- d) The **positive test** results are generally reliable.
- e) A **negative test** result will often suffice for return to school.



e

Antibody tests




Figure 4. Time kinetics of antibody response in coronavirus disease 2019 (COVID-19). The illustration

Antibody tests: Methods

- Enzyme-linked immunosorbent assay (**ELISA**)
- Lateral flow immunochromatography (LFI)




Figure 2. Overview of rapid diagnostic serological test. Rapid diagnostic tests (RDTs) are typically

Antibodies tests

- Serologic tests detect antibodies to SARS-CoV-2 in the blood
- Sensitivity of **IgM** :
 - by one week: **23** percent
 - by two weeks: **58** percent
 - by three weeks: **75** percent
- Sensitivity of **IgG** :
 - by one week: **30** percent
 - by two weeks: **66** percent
 - by three weeks: **88** percent
- Other studies have suggested that the rate of positive IgG approaches **100 percent by 16 to 20 days**

Antibody tests: **specificity**

- IgM and IgG antibodies detected on ELISA have more than **95%** specificity in the diagnosis of COVID-19
- **High titers of IgG** antibodies detected by ELISA demonstrate a positive correlation with **neutralizing antibodies**.

Antibody tests

- FDA has **not** authorized using antibody tests to **diagnose** SARS-CoV-2 infection
- CDC does **not** currently recommend using antibody testing as **the sole basis for diagnosis** of acute infection.

In certain situations, serologic assays may be used to support clinical assessment

1. Patient present late in their illnesses when used in conjunction with viral detection tests
2. If a person is suspected to have a post-infectious syndrome caused by SARS-CoV-2 infection

The duration of detectable antibodies is uncertain.

- **Detectable IgG at 8 weeks following infection** : Negative
 - **40** percent of asymptomatic patients
 - **13** percent of symptomatic patients
- Another study from Iceland:
 - Total Ig antibody tests were reactive in **90** percent
 - with titers increasing over the **first two months** after diagnosis
 - remaining steady for another **two months**

What type of personal protective equipment (PPE) do I need to use when I conduct testing?

- At a minimum, the use of **gloves, face mask, and eye protection** is necessary for all specimen handling and collection.
- For patients for whom crying, gagging, or coughing is likely; or for patients who are otherwise deemed as higher risk, such as high suspicion of SARS-CoV-2 infection based on household contacts, the addition of **gowns and N95 masks** is encouraged.

Should I additionally test for influenza during flu season?

- The range of symptoms for influenza and COVID-19 are similar
 - It is **not possible to differentiate** these two viral syndromes on the basis of symptoms alone
- **Coinfection** is entirely possible.

Coinfection was detected in 5.6 percent

- Detection of other respiratory pathogens (**does not exclude** COVID-19)
- In a systematic review of COVID-19 in 1183 children from 26 countries
 - a) *M. pneumoniae*** was most common (58 percent of coinfections)
 - b) Influenza** (11 percent)
 - c) RSV** (9.7 percent)

Other Laboratory findings

- The complete blood count
 - normal in most children
 - 17 %: Leukopenia
 - 13 %: neutropenia or lymphocytopenia
- C-reactive protein (CRP, >5 mg/L) and Procalcitonin (defined as >0.5 ng/mL)
 - Elevated in one-third
-
- **Elevated inflammatory markers and lymphocytopenia may indicate multisystem inflammatory syndrome in children (MIS-C)**
- Serum aminotransferases : elevated in 12 %
- Creatine kinase (CPK): elevated in 15 %

فاکتورهای پیش بینی کننده آزمایشگاهی پیشرفت بیماری در فرد بستری

یافته های آزمایشگاهی

- افت پیشرونده تعداد لنفوسیتها نسبت به تست پایه با و یا بدون انمی و ترومبوسیتوپنی.
- افزایش ۵۰ درصدی در LDH و یا CRP نسبت به تست پایه.
- کاهش GFR به زیر ۵۰ ml/min

* موارد زیر هم پیش بینی کننده پیشرفت بیماری است و در صورت درخواست مورد توجه قرار گیرد:

- Troponin
- PT, PTT, INR
- High ferritin (Ferritin > 500 ug/L)
- D-dimer(>1000 ng/ml¹)

Initial labs

- CBC with differential
- CRP; ESR
- D dimer
- PT / INR, PTT
- Fibrinogen

- LDH
- Troponin
- Procalcitonin *
- Ferritin
- VBG
- Serum Lactate

جدول ۲- آزمایشات اولیه

Predictors	Predictive factor	Cut off	Score
Lab Tests	Lymphopenia	According to COVID-19 algorithm in children*	2
	LDH** or	>500	2
		245-500	1
	CRP	>70mg/L	2
		40-70mg/L	1

*لنفوپنی عبارتست از میزان لنفوسیت کمتر از ۳۰۰۰ برای سنین ۱-۱۲ ماه ، کمتر از ۲۰۰۰ برای سنین ۱ تا پنج سال و کمتر از ۱۱۰۰ برای سنین بالاتر از پنج سال.
 **مقادیر LDH که در جدول آمده است برای سنین بعد از دوره نوزادی قابل قبول است.

جدول ۳- آزمایشات بیماران بستری در بیمارستان


آزمایش های روتین	
روز اول بستری (درخواست این آزمایشات و تکرار آن می تواند بر اساس نیاز فرد و به صلاحدید پزشک و متناسب با بیماری زمینه ای فرد نیز باشد):	
CBC-diff, ESR, Quantitative CRP or LDH, SGOT, CPK, SGPT, BUN/Cr, ALP, B, Ca, Mg, Na, K, P, U/A	
آزمایشات زیر بر اساس شرایط بالینی بیمار ممکن است درخواست شود:	
PT, PTT, INR D-dimer, LDH, Ferritin, ABG, Fibrinogen, IL6, NT-proBNP B/C (در صورت شک به عفونت باکتریال) Procalcitonin (شک به عفونت ثانویه باکتریال) Urine Prot/Cr	

Age-related lymphopenia defines as below:

- Between 2-6 years less than 1800 (microlit), and
- Over six years less than 1,500 (10⁹/lit) ;

رادیوگرافی قفسه سینه

- حساسیت عکس قفسه سینه در مراحل اولیه بیماری و یا در بیماری خفیف کم است.
- با پیشرفت بیماری تا ۷۰ درصد بیماران در بدو ستري و تا ۸۰ درصد در حين بستري غير طبيعي می شوند.
- یافته های شایع :
 - airspace opacities
 - ✓ به شکل Consolidation یا
 - ✓ Opacity Ground Glass (GGO)
- عمدتاً دو طرفه، محیطی و در قسمت های تحتانی ریه
- پیشرفت بیماری: White Lung



CXR ریه به ۶ منطقه تقسیم می شود. خط A در سطح دیواره تحتانی قوس آئورت و خط B به موازات سطح تحتانی ناف ریه چپ رسم می شود. A و D منطقه فوقانی، B و E منطقه میانی، C و F منطقه تحتانی.

<https://link.springer.com/article/10.1007/s11547-020-01200-3>

امتیاز صفر = طبیعی (No lung abnormalities)

امتیاز ۱ = اینفیلتراسیون بینابینی (Interstitial infiltrates)

امتیاز ۲ = اینفیلتراسیون بینابینی و آلوئولار (با ارجحیت بینابینی) (Interstitial and alveolar infiltrates (interstitial predominance))

امتیاز ۳ = اینفیلتراسیون بینابینی و آلوئولار (با ارجحیت آلوئولار) (Interstitial and alveolar infiltrates (alveolar predominance))

سى تى اسكن ريه

• -حساسيت بالا


• GGO (Ground Glass Opacity) **مولتى فوكال** يك طرفه يا دو طرفه

• موقعيت پريفراى، ساب پلورال و يا پريوسكولار


• به شكل گرد يا بالگوى Crazy paving

• وجود Halo Sign و يا Reverse Halo Sign

Crazy paving



Halo Sign or Reverse Halo Sign



سی تی اسکن ریه


• کدورت‌های Ground Glass معمولا در **روزهای اول** دیده می‌شود و با پیشرفت بیماری، Consolidation اضافه می‌شود.

• معمولا **لنفادنوپاتی** دیده نمی‌شود و **پلورال افیوژن** نادر و خفیف است.

• البته یک **CT نرمال** در اوایل رد کننده بیماری نیست

Thanks for your attention

Do I have the virus?



STAY AT HOME!

STAY AT HOME!

GO TO WORK!

0-7 days
DO I HAVE THE VIRUS?
 Take a pcr-test

7-21 days
DO I HAVE THE VIRUS – OR HAVE I HAD THE VIRUS?
 Take a serology test+a pcr-test if the first test is negative

21+ days
HAVE I HAD THE VIRUS?
 ABCLabs offers serology testing for immunity.

In the first phase (red light) with symptoms the Covid-19 virus can be detected by a PCR-test.
 In the second phase (yellow light) the immune system reacts with IgM production (short term protection) and starts to produce IgG and or IgA antibodies (long term protection). In this phase you may still carry the virus and we recommend PCR testing.
 In the third phase (green light) the long term protecting antibodies IgG and/or IgA have developed to help with immunity.

ABCLabs offers virus detection with PCR analysis, using the most accurate test kits on the market, with a sensitivity level of 99.6%.

*Disclaimer: This chart is for illustrative purpose only